Abstract 12054: Electro-anatomic Mapping Guided Endomyocardial Biopsy: A Systematic Review
Introduction: Electro-anatomic mapping (EAM) has been studied as a modality to improve the sensitivity and reduce false negative rates with endomyocardial biopsy (EMB). We systematically reviewed the literature describing EAM guided EMB.
Methods: An experienced librarian developed search strategies for Ovid MEDLINE, Ovid Embase, Ovid CDR, Cochrane Central, Scopus and Web of Science. There were no restrictions on language or publication date. Animal studies were excluded. Search strategy included MESH headings and keywords including endomyocardial biopsy and electroanatomic mapping.
Results: Out of 139 studies initially identified, 16 (9 case series, 7 case reports) were included in this systematic review. EAM guided EMB was performed in 152 patients and results of 241 biopsies were available for analysis. The most common indications for EAM guided EMB were suspected arrhythmogenic right ventricular cardiomyopathy (ARVC), myocarditis and cardiac sarcoidosis (CS). While fluoroscopic visualization of the bioptome close to mapping catheter was the most commonly utilized biopsy technique (n=7 studies), direct visualization of bioptome on CARTO (n=4) and on NavX (n=2) were used as well. Low voltage areas had abnormal myocardial histology more commonly (range 60-100%) than normal voltage areas (range 11-52%). Sensitivity of low voltage areas for abnormal myocardium ranged from 60% to 82%. EAM guided EMB appears safe and adverse events were noted in only one study (remote hemopericardium).
Conclusions: EAM guided EMB is a safe and efficacious method to improve the sensitivity and reduce the false negative rate of conventional fluoroscopy guided biopsy.
Author Disclosures: V. Vaidya: None. A. Deshmukh: None. K. Vasudevan: None. A. Farrell: None. L. Cooper: None. S. Kapa: None. P. Noseworthy: None. D. Packer: Research Grant; Significant; American Heart Association Foundation Award, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic CryoCath LP, NIH, St. Jude Medical, Siemens, Thermedical. Honoraria; Significant; Abbott Laboratories/Topera, Abiomed, Aperture Diagnostics, Biosense Webster, Boston Scientific, CardioFocus, CardioInsight, Johnson & Johnson Healthcare Systems, Johnson & Johnson, MediaSphere Medical, , Medtronic CryoCath, Siemens, St. Jude Medical, Topera. Other; Significant; Royalties: St. Jude Medical, Royalties: Analyze-AVW technology, Royalties: Wiley and Sons. S. Asirvatham: Honoraria; Modest; Abiomed, Atricure, Biotronik, Biosense Webster, Boston Scientific, Medtronic, Medtelligence, St Jude, Sanofi-Aventis, Wolters Kluwer, Elsevier, Zoll. Other; Modest; Patents: Aegis, Access Point Technologies, Nevro, Sanovas, Sorin Medical.
- © 2016 by American Heart Association, Inc.